Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/nep.14114 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy.
Kidney Int Rep
October 2024
Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
Article Synopsis
- The TESTING trial found that corticosteroids reduce kidney failure risk in patients with IgA nephropathy (IgAN), but they also increase serious side effects, highlighting the need for better biomarkers.
- This study focuses on urinary soluble CD163 (u-sCD163), suggesting it correlates with treatment response and kidney health in IgAN patients receiving steroid therapy.
- The results indicate that higher u-sCD163 levels are linked to better steroid responses and that corticosteroids significantly lower u-sCD163 levels, which may reduce the risk of kidney progression.
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial.
J Hematol Oncol
September 2024
Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, Jiangsu, China.
Article Synopsis
- Blinatumomab has shown promise as a key treatment for acute B-cell precursor lymphoblastic leukemia (BCP-ALL) when combined with pre-treatment chemotherapy to minimize side effects and CD19 selection pressure.
- A recent phase 2 trial involved 35 newly diagnosed patients who received reduced-dose chemotherapy followed by blinatumomab, resulting in a high complete remission rate of 94% after 2 weeks of treatment.
- With a median follow-up of 11.5 months, the treatment demonstrated excellent long-term outcomes, including a 97.1% one-year overall survival rate, suggesting that a less intensive approach can be both effective and well-tolerated for this leukemia type.
The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy.
Kidney Int Rep
July 2024
The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Introduction: The therapeutic effects of steroids in immunoglobulin A nephropathy (IgAN) global (TESTING) study reported that methylprednisolone reduces the risk of major kidney events in individuals with IgAN at high risk of disease progression compared to supportive care alone but is associated with increased serious adverse events (SAEs) primarily with full-dose therapy. The risk benefit balance of the reduced-dose methylprednisolone regimen is examined in this prespecified analysis of the reduced-dose cohort of the TESTING trial.
Methods: Between 2017 and 2019, patients with IgAN, proteinuria ≥1 g/d despite 3 months of renin-angiotensin-system blockade and estimated glomerular filtration rate (eGFR) 30 to 120 ml/min per 1.
Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study.
Cancers (Basel)
July 2024
Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
PTCY 50 mg/kg/day on days +3/+4 is an excellent strategy to prevent GVHD. However, its use is associated with adverse outcomes such as delayed engraftment, increased risk of infection, and cardiac complications. This pilot study evaluates the efficacy and toxicity of a reduced dose of PTCY (40 mg/kg/day) combined with tacrolimus in 22 peripheral blood HLA-matched alloHSCT patients.
View Article and Find Full Text PDF[A Case of Hormone Receptor-Positive Recurrent Breast Cancer Successfully Treated with Low-Dose Ethinyl Estradiol].
Gan To Kagaku Ryoho
June 2024
Dept. of Surgery, Sapporo Century Hospital.
The patient, an 83-year-old woman, was diagnosed with ER- and PgR-positive left breast cancer(T2N0M0, Stage ⅡA) at the age of 68. At the time, she underwent preoperative chemotherapy followed by Bp+Ax and postoperative radiotherapy to the conserved breast. She also received endocrine therapy as adjuvant therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!